El interés en corto de Emergent BioSolutions da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Emergent BioSolutions. Los datos de interés en corto se actualizan cada dos semanas.

Emergent BioSolutions (NYSE:EBS) Bolsa, Informe de interés en corto

Emergent BioSolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Inc

EMPIRE BANCSHARES INC by Empire Bancshares Inc.

Empire Bancshares Inc

<h3>Gainers</h3>
<ul>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock moved upwards by 66.4% to $6.4 during Thursday's regular session. The market value of their outstanding shares is at $6.6 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares increased by 49.13% to $3.46. The market value of their outstanding shares is at $6.1 million. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares rose 28.62% to $5.14. The company's market cap stands at $758.7 million. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) stock increased by 25.64% to $4.36. The company's market cap stands at $272.0 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock increased by 20.3% to $1.25. The market value of their outstanding shares is at $6.7 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock rose 18.51% to $7.04. The market value of their outstanding shares is at $368.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) stock decreased by 19.4% to $1.75 during Thursday's regular session. The market value of their outstanding shares is at $91.3 million. As per the news, the H1 earnings report came out yesterday. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares declined by 18.99% to $1.92. The company's market cap stands at $2.5 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares decreased by 14.47% to $5.64. The market value of their outstanding shares is at $8.2 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares declined by 13.31% to $8.34. The company's market cap stands at $13.0 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 11.02% to $0.6. The company's market cap stands at $4.5 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock decreased by 10.17% to $1.67. The market value of their outstanding shares is at $21.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADPT

ERNA

FBRX

FULC

KAPA

KTTA

LUCY

TBIO

TOVX

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Emergent BioSolution shares are trading higher after the company announced that two contract options have been secured to procure additional treatment courses of TEMBEXA to sustain the U.S. government's national preparedness posture against human smallpox.

Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) ("Emergent") today announced that two contract options have been secured to procure additional treatment courses of TEMBEXA&#xAE; (brincidofovir) to sustain the U.S. government's national preparedness posture against human smallpox. TEMBEXA&#xAE; is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The order is valued at $67.4 million and executes procurement options CLIN0004A and CLIN0005A under Emergent's existing <a href="https://www.globenewswire.com/Tracker?data=djyD7sABmBk1yf6GemRN-78PCdLUCUEILbW0T7FICIzw8ndOPvJSbqfFwkDZDrI_i4RfOeZpKX6kNcnggSlrYRtSPeFBZ9ukphhl3d-Yt1HxunOO_y0TbVCeKnD0LGRMafk1io2mxDTF9mMtUHtJC9Rm4DmfR-ByGrsuZ4G-Igt9x3GkusFXw8RKmrIdzCLrLvRB_mcW_1epmeIUWdtK-coN01OSB2IVx2QIjcCR_wFvA800MvXraKpUNWJaKnN3">10-year contract</a>.

News

Contracts

Emergent BioSolutions Announces The Execution Of Contract Options Valued At $67.4M To Procure Additional TEMBEXA To Support National Preparedness Efforts

On Wednesday, Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) said it secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox, and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41021297/emergent-biosolutions-confirms-approximately-400-million-in-orders-in-2024-2025-to-support-smallpo" rel="noreferrer noopener">mpox product portfolio</a>.
What Happened: The order includes the previously disclosed&nbsp;U.S. government contract modification&nbsp;to procure ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live), as well as CNJ-016&nbsp;[Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) contract options exercised <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39602092/why-is-vaccine-maker-emergent-biosolutions-stock-trading-higher-on-tuesday" rel="noreferrer noopener">in&nbsp;2023&nbsp;and&nbsp;2024</a>.
To date, in 2024, nearly $210 million in customer orders have been delivered for ACAM2000&nbsp;and VIGIV.
For the remainder of 2024 and into 2025, Emergent is confirmed to deliver more than $185 million in ACAM2000 and VIGIV orders.
&#8220;Emergent co1ntinues to be a trusted partner to supply medical countermeasures for biodefense and global health preparedness, and these incremental orders demonstrate our ongoing leadership to help address serious viral threats like smallpox and mpox,&#8221; said Joe Papa, president and CEO of Emergent.
Why It Matters: In August, the FDA approved Emergent BioSolutions&#8217; supplemental Biologics License Application (sBLA)&nbsp;to expand the indication for ACAM2000 to include preventing mpox disease in individuals at high&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40649541/mpox-vaccine-emergent-biosolutions-smallpox-vaccine-gets-fda-nod-for-expanded-use-for-individuals" rel="noreferrer noopener">risk for mpox infection</a>.
Shortly after, Emergent&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=EzQNYDD8pjtoG0gZzPCrG3pNpuayyfCXiLNpEwRuNQeXZCSjZPieHKbrFjIlQ6LthEsBPtCl2YoAr32DdkOrKgYmRck1tI9jw9Csclvb-DBrRN4ZcsnFimIlLvkIVTA7OMfhLX9Rz8PWUS6XTJRHZuvZv7FyFwtw1_p3I81lKppGQdmnoDbE1M1s2YOZlkfiobjdbi5T98mDUJI7CFCLnS-nY2jaaMEOuKWt-LKaI1g_E83TYZBq7F4mtGkYFfb026H5va42kZ2TP7mEmKP1aKHST2zxTD8uCiP51PpIG-38SyuoKHWlnseAJyL1HaG2poVAmXYZE9hDFMC9HVwRyLAsSMnZy3Mvv9v1Y5mCnq-ToHmuQfXCWDrekdJu5ywMj7CrT5OghPd5H2abWQMrZN0Jz5oizAyZlsfW8jrDxXY=" rel="noreferrer noopener">announced</a> that it submitted an Expression of Interest for the ACAM2000 vaccine to be assessed for Emergency Use Listing (EUL) with the&nbsp;World Health Organization&nbsp;(WHO).
In furtherance of its commitment to support mpox response efforts,&nbsp;Emergent has donated 50,000 doses of ACAM2000 for potential deployment across impacted countries across the African continent.
Last month, Emergent BioSolutions reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40226161/vaccine-maker-emergent-biosolutions-expects-deeper-losses-in-2024-stock-sinks" rel="noreferrer noopener">consensus of $190 million</a>.
The company reported an adjusted EPS loss of $(2.32), more than double the $(1.05) reported a year ago,&nbsp;missing the consensus of $(0.94).
Emergent BioSolutions updated its 2024 Revenue guidance from $1 billion—$1.1 billion to $1.05 billion—$1.125 billion, versus the consensus of $1.03 billion.
Price Action: EBS stock is down 3.7% at $5.88 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41024832/eli-lilly-touts-results-of-eu-approved-dermatitis-treatment-shows-sustained-disease-control-for-u" target="_blank" rel="noreferrer noopener">Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years</a>.</li>
</ul>
Photo: Unsplash

Biotech

Government

Health Care

Trading Ideas

General

Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines

Emergent BioSolutions shares are trading higher after the company announced  it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio.

Emergent BioSolutions Announced It Has Secured Approximately $400M In Orders In 2024 And 2025 Associated With Its Vaccinia, Smallpox And Mpox Product Portfolio

<a href="https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.">https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.</a>
&nbsp;
Los Angeles County health officials are reporting a significant uptick in mpox cases, prompting renewed calls for vaccination among&nbsp;high-risk&nbsp;groups.
The County's Department of Public Health announced that 52 mpox cases were reported in the past four weeks, compared to 24 in the previous&nbsp;four-week&nbsp;period.&nbsp;
About 70% of new cases in the last six months occurred in&nbsp;unvaccinated&nbsp;individuals.
Health officials strongly recommend vaccination for several high-risk groups, including men and transgender people who have sex with men or transgender persons, persons of any gender or sexual orientation who have sex or intimate physical contact with others in association with large public events or engage in commercial and/or transactional sex, and those living&nbsp;with&nbsp;HIV.
"Vaccination is an important tool in preventing the spread of mpox," the County health department said in a statement. The two-dose JYNNEOS vaccine is available at pharmacies for insured residents and at Los Angeles County Department of Public Health Clinics for free&nbsp;without&nbsp;appointments.
Officials advise residents to practice safe sex, limit sexual partners, and avoid intimate contact with anyone showing mpox symptoms, which include rash, fever, and swollen lymph nodes. Additional prevention measures include asking partners about symptoms, reducing the number of partners, and proper use of condoms&nbsp;and&nbsp;gloves.
The County emphasizes the importance of testing for those who develop symptoms consistent with mpox. The Department of Public Health is collaborating with healthcare providers and community organizations to intensify surveillance, contact tracing, and outbreak investigations to&nbsp;curb&nbsp;transmission.
Mpox, previously referred to as Monkeypox, is mainly spread through close physical contact. Residents seeking more information can visit<a href="http://ph.lacounty.gov/mpox"> ph.lacounty.gov/mpox</a> or call the Department of Public Health Call Center&nbsp;at&nbsp;1-833-540-0473.

Macro Economic Events

Economics

AEMD

APDN

CMRX

GOVX

MRNA

TNXP

VRAX

'Mpox Cases Double In Los Angeles County, Health Officials Urge Vaccination; Los Angeles County Public Health Officials Report Increase, Recommend Prevention Measures' - Pasadena Now

<a href="https://www.youtube.com/watch?v=ZFW3ONApp4w" title="https://www.youtube.com/watch?v=ZFW3ONApp4w">https://www.youtube.com/watch?v=ZFW3ONApp4w</a>

Macro Notification

Biden On Sudan Says End This War Now; Let's Move Quickly To Face Mpox Outbreak In Africa

-Reuters Citing Senior Administration Official

President Biden Will Announce Donation Of 1M MPox Vaccine Doses, At Least $500M To African Countries To Support Their Response To Outbreak

CDC Says No Cases Of Clade IA Mpox Have Been Reported Outside Central African Countries Where Clade IA MPVX Is Endemic

US To Stay Committed In Bringing Mpox Outbreak Under Control

Rodman &amp; Renshaw analyst Brandon Folkes reiterates Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

Analyst Ratings

Rodman & Renshaw Reiterates Buy on Emergent BioSolutions, Maintains $16 Price Target

Legal

Emergent Biosolutions Has Entered Into An Agreement To Resolve The Previously Disclosed Securities Class Action Litigation, Emergent Will Pay $40M To Settle Claims

Morocco Records First Case Of Mpox

Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) announced today that it was awarded a contract modification executing an option period by the&nbsp;Biomedical Advanced Research and Development Authority&nbsp;(BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the&nbsp;U.S. Department of Health and Human Services&nbsp;(HHS), valued at $41.9 million, for drug substance engineering and scale-up process validation, long term stability, and commercial readiness in support of its ongoing scale-up program for Ebanga&#x2122; (ansuvimab-zykl), a licensed treatment for Ebola virus disease (EVD).

Emergent BioSolutions Awarded R&D Option valued At $41.9M For Continued Advanced Development And Procurement Of Ebanga Treatment For Ebola

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Monday.
Shares of Methanex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) fell sharply in today's <a href="https://www.benzinga.com/markets/equities/24/09/40769930/methanex-to-buy-ocis-international-methanol-business-for-2-05b-details">pre-market trading.</a>
Methanex disclosed that it has entered into a definitive agreement to acquire OCI Global‘s international methanol business for $2.05 billion.
Methanex shares tumbled 6.3% to $39.79 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>C4 Therapeutics, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) shares dipped 17% to $4.48 in pre-market trading. C4 Therapeutics will reveal preliminary CFT1946 monotherapy Phase 1 clinical data at ESMO Congress 2024.</li>
<li>Lotus Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) shares fell 5.4% to $4.90 in pre-market trading after gaining around 6% on Friday.</li>
<li>Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) fell 4.8% to $112.23 in pre-market trading. Daiichi Sankyo and Merck&#8217;s Ifinatamab Deruxtecan showed response rates in extensive-stage small cell lung cancer in Phase 2 IDeate-Lung01 trial.</li>
<li>Mercer International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) shares declined 3.2% to $5.50 in pre-market trading. Adient will replace Mercer International in the S&amp;P SmallCap 600.</li>
<li>Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) shares fell 3.1% to $12.68 in pre-market trading.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) fell 2.3% to $13.97 in pre-market trading after gaining over 4% on Friday.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares slipped 2.3% to $7.34 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40767657/s-p-500-records-largest-weekly-decline-since-march-2023-as-nvidia-google-tumble-fear-greed-index">S&amp;P 500 Records Largest Weekly Decline Since March 2023 As Nvidia, Google Tumble: Fear &amp; Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>

CCCC

MEOH

MERC

Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session

CDC Says There Have Been No Reported Cases Of Clade I Mpox In The U.S. As Of September 6; In The U.S., Clade II Mpox Is Still Circulating At Low Levels

<a href="https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926">https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926</a>
&nbsp;
Senior Biden administration officials said Friday that the United States is preparing for the possible arrival of <a href="https://www.nbcnews.com/health/health-news/mpox-strain-spreads-cdc-who-stronger-warnings-rcna165155">a more severe version of mpox</a>, which has taken off in the Democratic Republic of Congo and other countries in Africa resulting in more than 600 deaths there.
As of Thursday, there have been more than 24,800 reported cases of this version of the virus, <a href="https://www.nbcnews.com/health/health-news/mpox-virus-outbreak-symptoms-2024-spread-rcna166778">known as clade 1</a>, so far this year, the World Health Organization said at a separate briefing Friday.&nbsp;The WHO declared the outbreak a<a href="https://www.nbcnews.com/health/health-news/who-declares-mpox-global-public-health-emergency-second-time-rcna166601"> global health emergency</a> in August.
Last month,<a href="https://www.nbcnews.com/health/health-news/sweden-confirms-first-case-mpox-strain-congo-rcna166763"> Sweden confirmed a case of clade 1</a>, the first known case outside of Africa, followed by a case in Thailand several days later. Both patients had spent time in Africa.
A different version of mpox, clade 2, triggered a global outbreak in 2022 and a surge of cases in the U.S. Clade 1 is more severe and can kill up to 10% of people infected, though recent death rates have been around 1% to 3.3%, <a href="https://www.cdc.gov/poxvirus/mpox/about/index.html">according to the CDC.</a>
On a call with reporters, senior administration officials said that as infections have risen in Africa, the U.S. has been gearing up for its own cases.&nbsp;
"We've been preparing for the arrival of clade 1 in the United States for many months now, especially as we saw the outbreak in DRC and neighboring countries accelerate," one official said.
The government is expanding its mpox surveillance efforts, primarily through wastewater analysis, and is reaching out to the medical community to educate members on what to watch for, including the severity of clade 1 and how it spreads, according to officials.
Officials said they're also making sure testing is more widely available.
Any doctor in the U.S. can order an mpox test that can be run through a national laboratory. If positive, it can be tested for clade 2. If those results are negative for clade 2, the doctor can make a presumptive diagnosis of clade 1; that diagnosis will need to be officially confirmed by the Centers for Disease Control and Prevention, according to officials.
The Jynneos mpox vaccine, given in two doses, is effective against both clade 1 and clade 2 of mpox.
The CDC's vaccine recommendation remains limited to anyone who is considered at high risk of catching the virus, mainly gay and bisexual men.&nbsp;
Most people with health insurance can get the vaccine at major pharmacy retail chains including CVS and Walgreens, the officials said. The vaccine is also available for free at public health departments and community health centers.
More vaccines are being held in the U.S. national stockpile, officials said, although they declined to say how many.&nbsp;
"There is a sufficient amount of vaccine for the U.S. population," an official said.&nbsp;
The U.S. is also working with government scientists and drug companies to develop potential new treatments. There are currently no approved treatments for mpox. The Food and Drug Administration has approved an antiviral treatment known as TPOXX for smallpox, which is closely related to mpox, although a recent clinical trial found that the drug is <a href="https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo">not effective against clade 1</a>.&nbsp;

'U.S. Prepares For Possible Arrival Of More Severe Strain Of Mpox; There Have Been Nearly 25,000 Cases Of The Clade 1 Version Of Mpox In Africa So Far This Year" - NBC

<a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523">https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523</a>
&nbsp;
Today, close to 100,000 mpox vaccine doses will arrive in the Democratic Republic of Congo (DRC), making these the first delivery of the vaccine to the country. A second delivery amounting to around 100,000 vaccines is expected to arrive in the coming days.
These vaccines are part of the 215,000 MVA-BN&#xAE; <a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4244">vaccine doses</a> that the European Commission's Health Emergency Preparedness and Response Authority (HERA) procured and pledged to share to affected countries in Africa as an immediate response to the mpox outbreak.
Via Team Europe, an additional 351,500 of doses from France, Germany, Spain, Malta, Portugal, Luxembourg, Croatia, Austria, Poland, and potentially some other Member States, will be donated to the Africa CDC to distribute to affected countries. This brings the total number of vaccine doses donated from Team Europe to at least 566,500, which includes the above 215,000 doses that were donated by HERA in cooperation with the Bavarian Nordic pharmaceutical company.
EU support for the mpox outbreak
This initiative is part of a comprehensive set of EU actions put in place as part of the EU Global Health Strategy, which represents the external dimension of a strong European Health Union and is a key component of Global Gateway, to support partners in the rest of the world.
The Commission is actively coordinating the response of EU Member States to the mpox outbreak via regular meetings of the HERA Board and the Health Security Committee, which allows prompt coordination when dealing with health threats.
The Emergency Response Coordination Centre (ERCC) is in contact with EU Member States given that, if activated, the EU Civil Protection Mechanism (rescEU) can be used to channel mpox vaccines and therapeutics to countries in need. Specialised expertise, medical items and equipment could also be deployed based on these needs.
Under the Global Gateway investment strategy, the Commission is committed to advancing public health in Africa. The Commission has focused on strengthening health systems, securing pharmaceutical supply chains, and developing local manufacturing through investment in infrastructure and a supportive regulatory environment. An example of this is the Team Europe Initiative on manufacturing and access to vaccines, medicines and health technologies (Mav+) and on Sustainable Health Security.
The European Centre for Disease Prevention and Control (ECDC) is supporting epidemiological work on the ground in the DRC, working with the Africa CDC to identify priority areas for mpox research, and is leading coordination of the Network of Major CDCs globally. HERA is also working with the Africa CDC with the aim of expanding access to mpox diagnostics and sequencing in the region, with a €9.4 million grant foreseen for early autumn.
The Commission has released €1 million in humanitarian aid to support care, prevention, epidemiological surveillance, risk communication and distribution of kits in the eastern DRC as well as €200,000 in Burundi to assist the Burundi Red Cross in preparing for and responding to the epidemic. Under the European Humanitarian Response Capacity (EHRC), in cooperation with the ECDC, two epidemiologists were deployed on 4 September to the DRC. In addition, the Commission provides regular humanitarian funding for surveillance programmes, including in Uganda and Kenya's camps and settlements and expertise to assist in the response.

Global

'First Delivery Of Mpox Vaccine Doses From The Commission Arrive Today In The Democratic Republic Of Congo' - European Commission

The New Term Loan maturity extends up to five years, through August 2029. Excess proceeds from the refinancing will result in additional cash to the balance sheet. Emergent also terminated its obligations under the senior term loan facility and the revolving credit facility under the Prior Credit Agreement.

Emergent Biosolutions Closed A New Credit Facility Agreement With Oak Hill Advisors For A Term Loan Of Up To $250M And Repaid Senior Term Loan Facility Dated October 15, 2018 Which Was Scheduled To Mature In May 2025

Emergent Biosolutions (EBS) has issued an update. Emergent BioSolutions Inc. secured a $250 million term loan on August 30, 2024, with lenders and ...

Emergent BioSolutions Secures $250M Loan and Adjusts Equity

Africa-based Aspen reportedly in talks for mpox vaccine production

Emergent Bio slips after financing deal

Bavarian Nordic stock slides on Moderna mpox vaccine study

Morocco reports first mpox case amid ongoing global outbreak

Emergent Bio to pay $40M to settle class action lawsuit

The 1-Minute Market Report September 22, 2024

U.S. to donate 1M mpox shots to address outbreak in Africa: report

Emergent Bio gains after confirming $400M orders for 2024/25

Emergent Bio gains after U.S. govt. order for smallpox therapy

ACTV

AFMC

AFSM

APNHF

APNHY

ARKK

AVUV

BAPR

BITO

BIZD

BVNKF

BVNRY

CHRS

CODX

COPX

CRMT

CRNC

DCOM

ICLN

ITOS

IVOO

IVOV

KCCA

KRBN

LSCC

MAGS

MLKN

MODV

MSOS

PALL

PAVE

PGNY

POWL

RHHBF

RHHBY

SIGA

SLVM

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPWRQ

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSLY

SSPY

SVAL

SYLD

TMDV

TPHD

TPLC

TPSC

UAUG

UFPT

UJAN

UMAR

UMAY

UOCT

UPRO

URNM

USMC

USMF

USVM

UTWO

Screenshot 2024-09-18 at 12.30.33 AM

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Press Releases

Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals

Emergent BioSolutions' ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

Management

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Financing

OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

Comments

Emergent BioSolutions

Interés en corto

Emergent BioSolutions (NYSE:EBS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL